HC Wainwright set a $33.00 price objective on Mersana Therapeutics (NASDAQ:MRSN) in a research report report published on Tuesday morning. The firm currently has a buy rating on the stock.
Other equities analysts have also issued research reports about the company. Leerink Swann restated an outperform rating on shares of Mersana Therapeutics in a research note on Wednesday, March 28th. Zacks Investment Research upgraded Mersana Therapeutics from a sell rating to a hold rating in a research note on Wednesday, April 18th. ValuEngine upgraded Mersana Therapeutics from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Robert W. Baird started coverage on Mersana Therapeutics in a research note on Monday, May 7th. They issued an outperform rating and a $30.00 target price on the stock. Finally, Cowen reiterated a buy rating on shares of Mersana Therapeutics in a research note on Monday, April 16th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $25.67.
Shares of NASDAQ:MRSN traded up $0.37 on Tuesday, hitting $18.90. 420 shares of the company’s stock were exchanged, compared to its average volume of 112,922. Mersana Therapeutics has a 12 month low of $14.65 and a 12 month high of $15.99. The company has a market cap of $383.38 million and a price-to-earnings ratio of -5.75.
Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Monday, May 14th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.07. The business had revenue of $3.06 million during the quarter, compared to the consensus estimate of $3.49 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. analysts forecast that Mersana Therapeutics will post -2.35 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. ArrowMark Colorado Holdings LLC grew its stake in Mersana Therapeutics by 88.4% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 899,773 shares of the company’s stock valued at $14,783,000 after purchasing an additional 422,062 shares during the last quarter. BlackRock Inc. grew its stake in Mersana Therapeutics by 41.7% in the first quarter. BlackRock Inc. now owns 818,004 shares of the company’s stock valued at $12,899,000 after purchasing an additional 240,705 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Mersana Therapeutics in the first quarter valued at about $2,681,000. Northern Trust Corp grew its stake in Mersana Therapeutics by 111.0% in the first quarter. Northern Trust Corp now owns 111,669 shares of the company’s stock valued at $1,761,000 after purchasing an additional 58,743 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Mersana Therapeutics by 10.1% in the fourth quarter. Geode Capital Management LLC now owns 63,173 shares of the company’s stock valued at $1,037,000 after purchasing an additional 5,821 shares during the last quarter. Institutional investors own 75.64% of the company’s stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.